Trials / Completed
CompletedNCT06393465
Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy
Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will examine the clinical effectiveness of Tafamidis in patients with Mixed Phenotype Transthyretin Amyloidosis using data that already exist in patients' medical records
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tafamidis | 61 milligrams under real world conditions |
Timeline
- Start date
- 2024-06-15
- Primary completion
- 2026-03-13
- Completion
- 2026-03-13
- First posted
- 2024-05-01
- Last updated
- 2026-03-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06393465. Inclusion in this directory is not an endorsement.